1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Keytruda Is King, But Merck Faces Questions About Business Development

 
• By Mary Jo Laffler

Keytruda continues to break records on the strength of its efficacy in lung cancer, and shows no signs of slowing down. But analysts were intrigued by repeated mentions of business development during Merck’s third quarter earnings call.

chess

Merck & Co. Inc.’s Keytruda may have taken the lead in global immuno-oncology sales, but the company isn’t resting on its laurels. As it treads a careful line of lauding pembrolizumab’s growth potential and avoiding becoming a one-product company, Merck used its third quarter earnings call Oct. 25 to push the idea of diversity. 

The company reported $9.7bn in pharmaceutical sales for the third quarter, up 5% year-over-year, driven primarily by oncology and hospital...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

AstraZeneca And Daiichi Sankyo’s Datroway Scores Survival Success In TNBC

 
• By Andrew McConaghie

Its overall survival win for Datroway could be an advantage over Gilead’s Trodelvy in triple negative breast cancer.

Jazz Looks To Label Expansion To Reverse Zepzelca Sales Slump

 
• By Alaric DeArment

The FDA approved the drug for combination with Roche’s Tecentriq in first-line maintenance of extensive-stage small cell lung cancer, while the NCCN added the combination to its treatment guidelines.

Genmab Takes On Big Commercial Challenge With Merus Buyout

 
• By Andrew McConaghie

The $8bn buyout could bring another blockbuster cancer therapy to Genmab but analysts think the firm has yet to prove itself in commercializing its own pipeline.

Roche Highlights Pipeline Transformed By Deals And ‘Raising The Bar’

 
• By Andrew McConaghie

The Swiss company believes new rigor in its internal decision-making and focus on best-in-class efficacy will deliver strong growth to 2030 and beyond.

More from Anticancer

IO Biotech Feels The Heat As US FDA Dashes Cylembio Filing Hopes

 
• By Manas Mishra

IO Biotech will need to conduct a fresh registrational study for melanoma vaccine hopeful Cylembio, which one analyst fears could result in a delay of more than three years to its launch plans.

Genmab Takes On Big Commercial Challenge With Merus Buyout

 
• By Andrew McConaghie

The $8bn buyout could bring another blockbuster cancer therapy to Genmab but analysts think the firm has yet to prove itself in commercializing its own pipeline.

AstraZeneca and Daiichi Sankyo Bolster Case For Enhertu In Early Breast Cancer

 
• By Alexandra Shimmings

Enhertu has bested Kadcyla in the DESTINY-Breast05 study in patients with high-risk HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment, topline data show. But hurdles remain to its widespread adoption.